Received Mar 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | Unknown | PO / MO |
The patient took one capsule of Vivotif vaccine once daily for four days instead of every other day; Case reference number US-BN-2024-000174, initially received from Med Communications on 09-Feb-2024 (reference number USBAV24-0291), is a spontaneous case received from a pharmacist and concerns a patient of unknown demographics. The patient's medical history and concomitant medications were not provided. On unspecified dates, the patient received the first, second, third and fourth dose of Vivotif vaccine (batch number: unknown), at an unknown dose, administered orally for typhoid immunization. As reported, the patient took Vivotif once daily for four days instead of every other day and taken four doses (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine. No further information was provided.; Reporter's Comments: A patient of unknown demographics received the first, second, third and the fourth dose of Vivotif vaccine for typhoid immunization. As reported, the patient took Vivotif once daily for four days instead of every other day and taken four doses, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medications were not provided. Inappropriate schedule of product administration has been considered as not related to the suspect, but to a human factor. This case is considered as non-serious.; Sender's Comments: A patient of unknown demographics received the first, second, third and the fourth dose of Vivotif vaccine for typhoid immunization. As reported, the patient took Vivotif once daily for four days instead of every other day and taken four doses, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medications were not provided. Inappropriate schedule of product administration has been considered as not related to the suspect, but to a human factor. This case is considered as non-serious.
Comments: None.